Bonnie Hepburn
Medical Practice in Escondido, CA
License number
New Jersey 25MA02960200
Issued Date
Jan 17, 1975
Expiration Date
Jun 30, 2005
Category
Medical Examiners
Type
Medical Doctor
Address
Address
Escondido, CA
Organization information
See more information about Bonnie Hepburn at bizstanding.comBonnie Hepburn MD
3639 Monte Real, Escondido, CA 92029
Industry:
Internist, Pediatric Rheumatologist
Phone:
(619) 743-0456 (Phone)
Bonnie Lee Hepburn
Professional information
Combination Of Proton Pump Inhibitor, Buffering Agent, And Prokinetic Agent
US Patent:
2005023, Oct 27, 2005
Filed:
Apr 15, 2005
Appl. No.:
11/107349
Inventors:
Gerald Proehl - San Diego CA, US
Warren Hall - Del Mar CA, US
Kay Olmstead - San Diego CA, US
Bonnie Hepburn - Escondido CA, US
Warren Hall - Del Mar CA, US
Kay Olmstead - San Diego CA, US
Bonnie Hepburn - Escondido CA, US
International Classification:
A61K031/4439
US Classification:
514338000
Abstract:
Pharmaceutical compositions comprising a proton pump inhibitor, one or more buffering agent and a prokinetic agent are described. Methods are described for treating gastric acid related disorders, using pharmaceutical compositions comprising a proton pump inhibitor, a buffering agent, and a prokinetic agent.
Novel Formulation, Omeprazole Antacid Complex-Immediate Release For Rapid And Sustained Suppression Of Gastric Acid
US Patent:
2005022, Oct 6, 2005
Filed:
Sep 10, 2004
Appl. No.:
10/938766
Inventors:
Bonnie Hepburn - Escondido CA, US
Barry Goldlust - San Diego CA, US
Barry Goldlust - San Diego CA, US
International Classification:
A61K031/4439, A61K009/20
US Classification:
424464000, 514338000
Abstract:
The present invention is directed to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a gastrointestinal disorder or disease, or the symptoms associated with, or related to a gastrointestinal disorder or disease in a subject in need thereof. In one aspect, the present invention provides a pharmaceutical composition comprising a proton pump inhibiting agent and a buffering agent for oral administration and ingestion by a subject. Upon administration, the composition contacts the gastric fluid of the stomach and increases the gastric fluid pH of the stomach to a pH that substantially prevents or inhibits acid degradation of the proton pump inhibiting agent in the gastric fluid and allows a measurable serum concentration of the proton pump inhibiting agent to be absorbed into the blood serum of the subject.
Methods Of Treating Systemic Lupus Erythematosus In Individuals Having Significantly Impaired Renal Function
US Patent:
2006021, Sep 28, 2006
Filed:
Feb 2, 2006
Appl. No.:
11/347426
Inventors:
Matthew Linnik - Solana Beach CA, US
Bonnie Hepburn - Escondido CA, US
Robert Bagin - Julian CA, US
Bonnie Hepburn - Escondido CA, US
Robert Bagin - Julian CA, US
International Classification:
A61K 48/00, C07H 21/02
US Classification:
514044000, 536023100
Abstract:
The invention provides methods treating lupus nephritis based in individuals with significantly impaired renal function, and methods of selecting individuals for treatment based on significantly impaired renal function. The treatment entails administration of a conjugate comprising a non-immunogenic valency platform molecule and at least two double stranded DNA epitopes, such as DNA molecules, which bind to anti-DNA antibodies from the patient. The invention also provides methods of identifying individuals suitable for treatment for lupus, based on assessing renal function to identify those individuals with significant impairment of renal function.
Methods Of Treating Systemic Lupus Erythematosus In Individuals Having Significantly Impaired Renal Function
US Patent:
2010015, Jun 17, 2010
Filed:
Oct 31, 2008
Appl. No.:
12/263239
Inventors:
Matthew D. LINNIK - Solana Beach CA, US
Bonnie HEPBURN - Escondido CA, US
Robert G. BAGIN - Julian CA, US
Bonnie HEPBURN - Escondido CA, US
Robert G. BAGIN - Julian CA, US
International Classification:
A61K 31/713, A61P 37/02, A61P 13/12
US Classification:
514 44 R
Abstract:
The invention provides methods treating lupus nephritis based in individuals with significantly impaired renal function, and methods of selecting individuals for treatment based on significantly impaired renal function. The treatment entails administration of a conjugate comprising a non-immunogenic valency platform molecule and at least two double stranded DNA epitopes, such as DNA molecules, which bind to anti-DNA antibodies from the patient. The invention also provides methods of identifying individuals suitable for treatment for lupus, based on assessing renal function to identify those individuals with significant impairment of renal function.
Methods Of Treating Systemic Lupus Erythematosus In Individuals Having Significantly Impaired Renal Function
US Patent:
2003011, Jun 19, 2003
Filed:
Aug 13, 2002
Appl. No.:
10/219238
Inventors:
Matthew Linnik - Solana Beach CA, US
Bonnie Hepburn - Escondido CA, US
Bonnie Hepburn - Escondido CA, US
International Classification:
A61K048/00
US Classification:
514/044000
Abstract:
The invention provides methods treating lupus nephritis based in individuals with significantly impaired renal function, and methods of selecting individuals for treatment based on significantly impaired renal function. The treatment entails administration of a conjugate comprising a non-immunogenic valency platform molecule and at least two double stranded DNA epitopes, such as DNA molecules, which bind to anti-DNA antibodies from the patient. The invention also provides methods of identifying individuals suitable for treatment for lupus, based on assessing renal function to identify those individuals with significant impairment of renal function.
Novel Formulation, Omeprazole Antacid Complex-Immediate Release For Rapid And Sustained Suppression Of Gastric Acid
US Patent:
2004024, Dec 9, 2004
Filed:
Feb 20, 2004
Appl. No.:
10/783871
Inventors:
Bonnie Hepburn - Escondido CA, US
Barry Goldlust - San Diego CA, US
Barry Goldlust - San Diego CA, US
International Classification:
A61K031/4439
US Classification:
514/338000
Abstract:
The present invention is directed to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a gastrointestinal disorder or disease, or the symptoms associated with, or related to a gastrointestinal disorder or disease in a subject in need thereof. In one aspect, the present invention provides a pharmaceutical composition comprising a proton pump inhibiting agent and a buffering agent for oral administration and ingestion by a subject. Upon administration, the composition contacts the gastric fluid of the stomach and increases the gastric fluid pH of the stomach to a pH that substantially prevents or inhibits acid degradation of the proton pump inhibiting agent in the gastric fluid and allows a measurable serum concentration of the proton pump inhibiting agent to be absorbed into the blood serum of the subject.